Will Eli Lilly’s Rezvoglar Be Able To Compete With Interchangeable Semglee?
FDA Approves Second Insulin Glargine Biosimilar Rival To Lantus
The FDA has approved the second biosimilar insulin glargine rival to Lantus, in the form of Eli Lilly’s Rezvoglar. However, Viatris’ recently relaunched Semglee version has an interchangeability designation on its side.
